Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0103)
Name
Deferoxamine
Synonyms
deferoxamine; Desferrioxamine B; 70-51-9; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; Deferrioxamine; Deferoxamin; Deferoxaminum; Desferin; Desferan; Desferex; Desferral; Desferrin; DFOM; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; NSC-527604; Deferoxamina; Ferrioxamine B, N-benzoyl-; Desferoxamine b; N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide; Dfo-b; J06Y7MXW4D; CHEBI:4356; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; Ba 33112; Ba-33112; NSC527604; 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamine (USAN); DEFEROXAMINE [USAN]; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid; N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Desferriferrioxamin B; MLS002702118; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina [INN-Spanish]; Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; Ba 29837; NSC268993; NSC644468; HSDB 3311; SMR000058548; EINECS 200-738-5; UNII-J06Y7MXW4D; BRN 2514118; Cordaneurin; Desferrioxamin; Perineurin; Desferioxamine B; desferrioxamine-B; C25H48N6O8; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide; N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid; N-[5-{3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido}pentyl]-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propionohydroxamic acid; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-; deferoxamine-mesylate; Desferal (Salt/Mix); Spectrum_000892; 1950-39-6; Prestwick0_000725; Prestwick1_000725; Prestwick2_000725; Prestwick3_000725; Spectrum2_001155; Spectrum3_000376; Spectrum4_000311; Spectrum5_000827; DEFEROXAMINE [MI]; DEFEROXAMINE [INN]; CHEMBL556; DEFEROXAMINE [HSDB]; EC 200-738-5; DEFEROXAMINE [VANDF]; SCHEMBL34571; BSPBio_000650; BSPBio_002131; KBioGR_000922; KBioGR_002429; KBioSS_001372; KBioSS_002435; 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane; cid_62881; N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide; DEFEROXAMINE [WHO-DD]; DivK1c_000082; Ba 29837 (Salt/Mix); SPBio_001109; SPBio_002589; BPBio1_000716; CGH-749B; ICL-749B; DTXSID7022887; BDBM47715; KBio1_000082; KBio2_001372; KBio2_002429; KBio2_003940; KBio2_004997; KBio2_006508; KBio2_007565; KBio3_001351; KBio3_002908; cMAP_000047; NINDS_000082; HMS3604E17; BCP16524; HY-B1625; LMFA08020169; WLN: Z5NQV/2VM5NQV/ 21; DEFEROXAMINE, Deferoxamine Mesylate; AKOS016004824; DB00746; IDI1_000082; SMP2_000121; NCGC00178802-01; NCGC00178802-02; NCGC00178802-03; MS-30181; NCI60_002181; SMR001550278; SBI-0051332.P003; AB00053447; CS-0013559; C06940; D03670; F11488; AB00053447_14; EN300-19748908; Q419618; Q-200933; BRD-K09821361-066-05-0; BRD-K09821361-066-06-8; BRD-K09821361-066-08-4; BRD-K09821361-066-13-4; BRD-K09821361-066-15-9; BRD-K09821361-066-16-7; 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid; N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide; N~4~-{5-[acetyl(hydroxy)amino]pentyl}-N~1~-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N~1~-hydroxybutanediamide; Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-

    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C25H48N6O8
IUPAC Name
N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide
Canonical SMILES
CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
InChI
InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
PubChem CID
2973
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Ischemia/reperfusion injury ICD-11: DB98
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Necroptosis hsa04217
Cell Process Cell ferroptosis
Cell necroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Male Sprague-Dawley (SD) rats (250-270 g) were purchased from the Laboratory Animal Center, Xiangya, School of Medicine, Central South University, China. A left thoracotomy was carried out in the fourth intercostal space and the heart was exposed via opening the pericardium. Blockage of the left coronary artery was conducted via clamping the snare against the heart surface. Reperfusion was performed by release of the snare. To establish the I/R injury model, the rat hearts were subjected to 1 h-ischemia plus 3 h-reperfusion.

    Click to Show/Hide
Response regulation The combination of ponatinib with deferoxamine reduces myocardial ischemia/reperfusion (I/R) injury via simultaneous inhibition of necroptosis and ferroptosis.
References
Ref 1 Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis. Eur J Pharmacol. 2021 May 5;898:173999. doi: 10.1016/j.ejphar.2021.173999. Epub 2021 Mar 3.